Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
4 min read
Review and Prospects of CYP1A2 Inhibitors
21 September 2023
Recombinant Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1A subfamily of the CYP1 family and is encoded by the CYP1A2 gene.
Drug Insights
5 min read
An In-depth Analysis of Sotagliflozin's R&D Progress and Mechanism of Action on Drug Target
21 September 2023
This article summarized the latest R&D progress of Sotagliflozin, the Mechanism of Action for Sotagliflozin, and the drug target R&D trends for Sotagliflozin.
Latest Hotspot
3 min read
The first patient receives treatment from NeuroBo Pharmaceuticals in their Phase 2a Clinical Trial studying DA-1241
21 September 2023
NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.
Drug Insights
4 min read
Selumetinib: Detailed Review of its Transformative R&D Success
21 September 2023
This article summarized the latest R&D progress of Selumetinib, the Mechanism of Action for Selumetinib, and the drug target R&D trends for Selumetinib.
Advanced Tech.
7 min read
Important Research Area in Life Science: Growth Factors
21 September 2023
Growth factors represent a class of polypeptides that regulate cell growth and various other cellular functions through binding with specific, high-affinity cell membrane receptors.
Drug Insights
4 min read
Peramivir Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
20 September 2023
This article summarized the latest R&D progress of Peramivir, the Mechanism of Action for Peramivir, and the drug target R&D trends for Peramivir.
Latest Hotspot
3 min read
The US has sanctioned Ojjaara (momelotinib), the the first and only therapeutic agent for anemia
20 September 2023
GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.
Drug Insights
4 min read
Unleashing the Power of Pantethine: A Comprehensive Review on R&D Breakthroughs
20 September 2023
This article summarized the latest R&D progress of Pantethine, the Mechanism of Action for Pantethine, and the drug target R&D trends for Pantethine.
Advanced Tech.
5 min read
An effective method to ward off viral intrusions: Toxoid Vaccine
20 September 2023
Toxoid Vaccine is essentially a bacterial toxin that is rendered harmless due to processing.
Drug Insights
5 min read
A Comprehensive Review of Pacritinib's R&D Innovations and Drug Target Mechanism
20 September 2023
This article summarized the latest R&D progress of Pacritinib, the Mechanism of Action for Pacritinib, and the drug target R&D trends for Pacritinib.
Latest Hotspot
3 min read
Harpoon Therapeutics shares progress on HPN217 development with AbbVie
20 September 2023
Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.
Drug Insights
4 min read
Pharmaceutical Insights: Nitrofurazone's R&D Progress and its Mechanism of Action on Drug Target
20 September 2023
This article summarized the latest R&D progress of Nitrofurazone, the Mechanism of Action for Nitrofurazone, and the drug target R&D trends for Nitrofurazone.